Irinotecan is a first line chemotherapeutic agent for colorectal carcinoma and well known for debilitating diarrhoea caused by mucositis. Tlr4, a pattern recognition receptor, has been implicated in irinotecan -induced mucositis due to its activation of downstream inflammatory pathways and interaction with luminal microbes. Tlr4 deletion has been reported to attenuate mucosal injury in preclinical models of mucositis, hypothesised to occur by blockade of Il-6 production. As such, the current study aimed to determine the relationship between Tlr4 and Il-6 in the context of irinotecan induced mucositis.
research is required to determine if it is via a direct or indirect mechanism. In the future, Il-6 may be targeted therapeutically to ameliorate symptoms of mucositis.
INTRODUCTION:
Irinotecan is a DNA topoisomerase I-targeted chemotherapeutic agent, approved as a first line agent for metastatic colorectal cancer 1 . It causes exceptionally high rates of gastrointestinal (GI) mucositis in the form of severe diarrhoea, leading to delays in therapy, dose reductions or in severe cases, discontinuation of treatment 2 . The pivotal phase III clinical trials of irinotecan found it was associated with, severe diarrhoea in 20-35% of cases 3, 4 .
Irinotecan-related diarrhoea is biphasic. A cholinergic-type diarrhoea occurs within 24 hrs of administration and can be managed with atropine 5 . Of serious concern is the late-onset diarrhoea which occurs 24 h after irinotecan administration. It is associated with severe inflammation within the small and large intestine mucosa and lacks an effective management intervention. Although, there is limited information about the inflammatory events that lead to severe irinotecan-induced diarrhoea 6 ; the interaction between the gut microbiome 7 and Toll like receptor 4 (Tlr4) signalling 8 has gained interest.
Tlr4 is an innate immune receptor expressed on intestinal epithelial cells 9 and immune cells of lamina propria, that exists in homeostasis with the intestinal environment 10 . Recent in vivo research has found Tlr4 to be a key mediator of irinotecan-induced mucositis 11 and mice lacking Tlr4 are protected from severe irinotecan-induced mucositis 11 .
Irinotecan is metabolised to cytotoxic SN-38 by hepatic or GI carboxylesterase, which causes irreversible DNA damage. After glucuronidation by liver glucuronyltransferase (UGA1T1), inactive SN-38G is excreted into the intestine for elimination. However, in the intestinal lumen, bacterial βglucuronidases regenerate toxic SN-38 from SN-38G 12 . This unique metabolic pathway not only results in high levels of intestinal toxicity, but also emphasises a key role played by gut microbiome 7 . Although irinotecan causes entire intestinal damage, ileum and colon are the most severely affected 13 . SN-38 is hypothesised to interact with Tlr4 at the MD-2 co-receptor binding pocket 14 . Tlr4/MD-2 receptor activation recruits adaptor protein MyD88 resulting in nuclear factor-κB (NF-κB) activation 15 . This causes downstream signalling and production of pro-inflammatory cytokines including tumour necrosis factor-α (Tnf-α), interleukin-1β (Il-1β), interleukin-6 (Il-6) 15 . Of this trio of cytokines, Il-6 is pivotal in setting of chronic inflammatory disease, including inflammatory bowel disease (IBD) 16 . Fig. 1 . Pathways for IL-6 production. Direct IL-6 production occurs through the activation of a receptor formed by two distinct subunits, an alpha subunit for ligand specificity and glycoprotein (GP) 130. Binding of IL-6 to its receptor (IL-6R) initiates cellular events including JAK kinases, which when phosphorylated, activates signal transducers and activators of transcription-3 (STAT3). This then translocates to the nucleus resulting in the production of IL-6. Indirect IL-6 production is mediated through innate immune receptor, Toll-like receptor 4 (TLR4). TLR4 is expressed on glial, immune and intestinal epithelial cells with bacterial lipopolysaccharide (LPS) as its primary ligand. Upon LPS binding, TLR4 undergoes a conformational change resulting in the recruitment of TIR domains containing adaptor molecules. In particular, myeloid differentiation primary response (MyD)88dependent signalling results in nuclear translocation of nuclear factor kappa B (NF-κB) and the subsequent production of IL-6 16. National Health and Medical Research Council (Australia) Code of Practice for Animal Care in Research and Training (2013) .
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Experimental design
Female BALB/c-wild-type (WT) and BALB/c-Tlr4 -/-billy (Tlr4 KO) mice (n =48) weighing between 18 and 25 g (10-13 weeks) were used. The mice are described in detail else where 13 . Briefly, mice were given 270 mg/kg of intraperitoneal (i.p) irinotecan hydrochloride (provided by Pharmacia/Pfizer) in a sorbitol/lactic acid buffer (PH 3.4). Control mice were given the sorbitol/lactic acid buffer only.
Atropine (0.03 mg/kg) was administered subcutaneously (s.c) to all mice prior to treatment to reduce the cholinergic diarrhoea. Mice were randomly assigned to treatment groups. Mice were anaesthetised using 200 mg/kg i.p. ilium sodium pentobarbital (60 mg/mL), and blood collected from the facial vein.
Mice were killed at 6, 24, 48, 72 hours by transcardial perfusion with cold, sterile 1 × PBS (pH 7.4) followed by 4% paraformaldehyde (PFA) in 0.1 mol/L PBS (pH 7.4) 20 . Ileum and colon tissue of mice killed at 6 and 72 h were used in my project. Groups allocations are shown in Fig.1 .
RNA extraction
Total RNA was extracted from tissues using the NucleoSpin® RNA II kit, as per manufacturer's instructions (Macherey-Nagel, Germany). After series of filtration and washing steps, extracted RNA 
RESULTS:
Transcript expression
Relative quantification of Il-6 and Il-6R transcript expression in tissue homogenates was conducted by RT-PCR. No significant difference between treatment group or genotype was found for Il-6 at 6 or 72 h in ileum or colon (Fig 2) . 
Protein expression
The tissue location and quantity of Il-6 and Il-6R protein was assessed by immunofluorescence.
Positively stained cells were present in the lamina propria, blood vessels and peyer's patches, while distinct epithelial staining was seen for Il-6R.
Within ileum tissue, irinotecan treatment caused a significant increase in Il-6 staining at 6 h in wildtype mice compared to controls. This effect was not observed in Tlr4 KO mice. Il-6 staining was also significantly less in irinotecan treated Tlr4 KO mice compared to wild type mice at 6 h There were no differences between groups at 72 h ( Fig. 4 ). Within colon tissue, irinotecan treatment caused a significant increase in Il-6 staining at 6 h in wildtype mice compared to controls. This effect was not observed in Tlr4 KO mice. Il-6 staining was also significantly less in irinotecan treated Tlr4 KO mice compared to wild type mice at 6 h There were no differences between groups at 72 h (Fig.5 
DISCUSSION:
Mucositis in the form of severe diarrhoea is a debilitating adverse effect of irinotecan 2 . In previous studies, Tlr4 KO mice have shown reduced gut inflammation, Il-6 protein levels and diarrhoea compared to WT mice following irinotecan treatment 18. As such, it was hypothesised that Il-6 upregulation drives chemotherapy-induced mucositis and its production is mediated by Tlr4 activation.
This study investigated the link between Tlr4 and Il-6 signalling in the context of irinotecan-induced mucositis.
Il-6 was significantly upregulated in WT irinotecan treated mice as compared to the control group at 6 h in ileum and colon. This finding is supported by previous research 13 , that showed significant Il-6 upregulation in WT irinotecan treated mice at 6 h 13 and rats at 12 h 6 . While, Tlr4 KO mice in our study showed significantly reduced intestinal Il-6 protein expression compared to WT mice treated with irinotecan at 6 h as measured by immunofluorescence. Previous work had shown prevention of irinotecan-induced Il-6 upregulation using ELISA 13 . Although quantitative, ELISAs are limited in their interpretation due to the inability to visualise the location of protein expression. In contrast, immunofluorescene provides an opportunity to determine the location of Il-6 expression in the tissue structure. The cells expressing Il-6 as seen under confocal were located in lamina propria of ileum and colon, paeyers patches and blood vessels. This can be explained by the fact that Il-6 is secreted by macrophages produced from circulating monocytes, attracted to site of inflammation. While resident macrophages are responsible for maintaining intestinal homeostasis and rarely secrete pro inflammatory cytokines 23 .
Tlr4 activation has already been hypothesised to be a key driver of irinotecan induced mucositis that is targetable for clinical management 24 . Pre-clinical 25 and clinical 26 research indicated upregulated Tlr4 expression following irinotecan administration and radiotherapy respectively. Tlr4 KO mice had shown significant reductions in diarrhoea, weight loss 11 and intestinal apoptosis as compared with WT mice after irinotecan administration 13 . On the contrary, a non-specific Tlr4 antagonist, (-)-naloxone, was not effective in reducing irinotecan-induced mucositis in Albino rats 24 . Moreover, Tlr4 antagonist, (-)-naloxone was associated with increased breast tumour growth and reduced irinotecan efficacy in Albino rats 24 . This emphasises the need for pharmacological inhibition of signalling products of Tlr4 for prevention of mucositis. Of the products of Tlr4 signalling, Il-6 has been found to be implicated in various inflammatory disorders especially IBD 27 .
In the view of current study, it can be hypothesised that interruption of Tlr4 signalling prevents signals that normally lead to Il-6 upregulation. Yet it is not clear if Tlr4 directly stimulates production of Il-6 from Il-6R-expressing macrophages and epithelial cells or indirectly by activation of NF-κB in cells responding to damage signals 19 . Although Tlr4 seems to regulate Il-6 production, an additional layer of complexity is expected to exist. The possibility arises because Tlr4 KO tissues in our study showed some degree of staining for Il-6, indicating that besides Tlr4, there may be some other factors responsible for Il-6 production. The five-phase model of mucositis presented by Sonis 15 implies production of reactive oxygen species (ROS) as a first step in initiation of mucositis. Further research indicated that ROS is capable of activating NF-κB producing Il-6 28, 29 and Tnf-α in alveolar macrophages 30 and clinically inhibition of mitochondrial ROS production inhibits production of Il-6
and Tnf-α 31 . The impact of ROS on Il-6 production in mucositis has not been studied so far. This research provides solid foundation to determine if ROS constitutes an important stimulus in Il-6 production from macrophages in irinotecan induced mucositis. ROS also appears to exacerbate LPS mediated Il-6 production 28 ; which is a potent Tlr4 agonist. Hence, a variety of different stimuli activate Il-6 which then serves as a chemo-attractant for other inflammatory cytokines. As such, while the results in this study and that of others support Tlr4-dependent Il-6 production, it is highly likely that Il-6 remains stimulated by other inflammatory pathways independent of Tlr4 activation.
cytokine that is elevated in the pathway of irinotecan-induced mucositis, before other cytokines can enter the inflammatory cascade, highlighting a key point between direct cytotoxic damage and secondary indirect tissue injury. This is supported by preclinical 6, 32 and clinical research 33 that Il-6 appears in mucositis pathway as early as 6 h 13 , causing infiltration of apoptosis resistant T cells and possibly serving as a chemo-attractant for Tnf-α and Il-1β producing cells that are elevated at 24 and 48 h respectively 13 . Il-1β and Tnf-α establish a positive feedback amplification of Il-6 production from NF-κB hence, potentiating the epithelial cell damage 16 . Blocking Il-6 production may also block production of other inflammatory cytokines by infiltrating immune cells. As such, therapeutically targeting Il-6 may an ideal approach to managing side effects of irinotecan without impacting on the direct cytotoxic properties of irinotecan and negating the challenges in specifically targeting intestinal Tlr4.
Il-6 inhibition has been investigated in other benign inflammatory disorders. The anti-Il-6 antibody, tocilizumab, has successfully been used in rheumatoid arthritis 34 . Moreover, in a clinical research, an Il-6 antibody (PF-04236921) has shown higher response and rates of remission in Crohn's disease than placebo therapy 35 . Clinically, use of anti Il-6 monoclonal antibody has shown to reduce the severity of mucositis in multiple myeloma patients 36 . Yet further research is needed for potential use of anti Il-6 antibody in mucositis.
Talking about Il-6 signalling without mentioning Il-6R is not fair at all. So far, our researchers seem to be interested in sIl-6R owing to its pro-inflammatory nature 34 and membrane bound Il-6R seems to be neglected for over a decade. So, in addition to tissue expression of Il-6, I also investigated the expression of its receptor Il-6R to explore its potential contribution to irinotecan induced mucositis. Il-6R is typically expressed on hepatocytes, spleen and immune cells 16 . Il-6 mediates its anti-inflammatory properties (regeneration and growth) by cis signalling. while proinflammatory pathways are mediated via trans signalling. As such, I also hypothesized that irinotecan induces mucositis is dependent on Tlr4 mediated Il-6R expression.
Irinotecan caused a significant increase in Il-6R expression in the ileum and colon. While the expression was significantly decreased in Tlr4 KO mice compared to WT controls in colon, I found no significant difference between two genotypes in ileum. The difference between regions may be explained by the underlying level of immune activation in colon related to increased microbial load 37 and its macrophage population 38 . This can further be explained by the finding that colon has high Tlr4 expression as compared to ileum 39 . Importantly, I observed clear Il-6R expression on epithelial cells. This finding contradicts research that implies that Il-6R is expressed only on hepatocytes and macrophages 16 . However, research dating back two decades has indicated that this receptor was expressed on intestinal epithelial cells 40, 41 . Research in the late 90's has indicated that Il-6R initially undetectable in foetal small bowel was expressed in intestine postnatally 42 . However, to the best of our knowledge there seems to be no latest follow up on this finding. More precisely, very few studies have shown a biological effect of Il-6 cis signalling on epithelial proliferation and mucosal barrier integrity in vitro, suggesting Il-6R is expressed on epithelial cells 43 . These findings therefore highlight a potential avenue for future research to delineate the expression and biological significance of epithelial Il-6R in intestinal homeostasis and inflammation. In addition to quantifiable expression, the localisation of Il-6R was affected by irinotecan. While untreated WT animals showed a small amount of epithelial Il-6R expression, owing to its role in crypt/villus maturation, growth and development 40 , Il-6R was preferentially expressed in the immune cells of lamina propria and blood stream.
In contrast, irinotecan-treated groups showed upregulation of epithelial Il-6R in ileum and colon.
The epithelial expression which was distinct at 6 h in irinotecan treated mice seems to be regulated by Tlr4 in colon. Our finding is supported by previous research that indicates that LPS (a potent Tlr4 agonist) causes upregulation of membrane bound Il-6R on intestinal epithelium, while it downregulates the receptor on macrophages 40 , which seems to be result of shedding to produce sIl-6R for inflammatory reactions 44 . However, it is not clear why the epithelial Il-6R is upregulated in irinotecan treated mice. A possibility exists that, just like the paradoxical role of Tlr4 in acute 45 and chronic inflammation 9 , epithelial Il-6R expression may be increased as a protective measure to combat mucositis. This is supported by evidence indicating the increase in intestinal perforations in rheumatic arthritis patients under therapy with tocilizumab, a human anti-Il-6R antibody, when compared to therapy with conventional disease-modifying anti-rheumatic drugs 46 Together, this suggests that cis signalling may contribute to intestinal repair during inflammatory response; the regenerative and inflammatory processes may be going side by side in intestinal injury in which Il-6-dependent regeneration may be completely overridden by the inflammatory response.
The presence of detectable Il-6 and Il-6R expression in non-inflamed intestinal tissues is of interest.
This suggests that these proteins, in health, may be required to maintain homeostasis in the intestinal mucosa. Interestingly, besides Il-6R expressing on epithelium and in lamina propria cells, we found Il-6R expression in submucosal cells in ileum. Due to limited time and resources, we could not assess the type of cell, yet based on its shape and location, it is possibly the glia or ganglion of sub mucosal plexus. This possibility is supported by a study investigating link between Tlr4 and irinotecan induced pain 13 . Our study raises suspicion of Tlr4 mediated Il-6R expression, it is quite possible irinotecan induced pain might be regulated by Tlr4 mediated Il-6R expression in enteric nervous system. Another study indicates the expression of Il-6 in enteric glia cells in rats 48 .
Moreover, inhibition of Il-6R in vivo in the irritable bowel syndrome rat model reduced visceral pain sensitivity 49 indicating the Il-6R expression on in enteric glia cells. In order to understand this mechanism in more detail and identify translatable aspects for pain management, further preclinical research is required.
Besides the protein expression, Il-6 and Il-6R mRNA showed no significant difference between genotypes or treatments at either the early or later time point in the ileum and colon. This finding contradicts with our results for protein expression. The possible reason may be that changes in Il-6 and Il-6R transcript occurred before the tissue was collected. This can be further explained by fact that different genes are upregulated at different time points in response to stress, expressing as early as 1 h 50 . Other mechanisms like post-translation processing, reduced internalisation and breakdown of Il-6R, changes in the ratio of soluble to membrane-bound Il-6R and gp130 levels might also be controlling the measurable increase in Il-6 and Il-6R. However, future study needs to be done to explore these potential mechanisms.
Importantly, the concept of Tlr4 mediated Il-6 production in irinotecan induced mucositis remains speculative and therefore warrants further research to determine dual role of mysterious Il -6R in intestinal mucositis and its regulation by Tlr4. Similarly, the conclusions drawn in this study must be interpreted with appropriate recognition of the study limitations. For example, our study used archived samples and RT PCR is on whole tissue, while using mucosal scraping may have been more informative to determine epithelial expression of Il-6R. Moreover, our study provides no information about shedding of Il-6R to sIl-6R. Future research elucidating the cells responsible for shedding of Il-6R and production of Il-6 could be achieved by flow cytometry. We can extend our research in future by using colorectal tumour bearing mice to investigate effects of Tlr4 deletion on irinotecan induced mucositis. Previously, clinical research has indicated that Il-6 is accompanied by a higher expression in intestinal epithelium of CRC patients as compared to controls 41 .
CONCLUSION:
Our results support previous findings that Tlr4 KO mice have an impaired Il-6 response and reduced diarrhoea suggesting that targeting Il-6 may be more sensible approach to prevent irinotecan-induced mucositis. As such, we suggest that IL-6 may be a more promising therapeutic target to prevent or reduce the severity of GI mucositis caused by irinotecan and should form the basis of new research models.
